Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Heart Failure
100%
Patients with Obesity
100%
Cardiovascular Outcomes
100%
SELECT Trial
100%
Semaglutide
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
68%
Major Adverse Cardiovascular Events
43%
Placebo
37%
Cardiovascular Mortality
25%
Patients with Heart Failure
25%
Hazard Ratio
12%
Once-weekly
12%
Baseline Characteristics
12%
All-cause Mortality
12%
History of Heart Failure
12%
Subcutaneous Semaglutide
12%
Overweight/obesity
12%
Heart Failure Subtype
12%
No Significant Difference
6%
Placebo-controlled
6%
Clinical Outcomes
6%
High Incidence
6%
Hospital Visits
6%
Serious Adverse Events
6%
Block Size
6%
Nonfatal Myocardial Infarction
6%
Composite Endpoint
6%
Improved Outcomes
6%
Obesity Treatment
6%
Event Rate
6%
Cardiovascular Hospitalizations
6%
Response System
6%
Randomized Double-blind
6%
Interactive Web Response
6%
Failure Hazard
6%
Target Dose
6%
Novo Nordisk
6%
Clinical Events
6%
Stroke Mortality
6%
New York Heart Association
6%
Random Assignment
6%
Nonfatal Stroke
6%
Diuretic Use
6%
41 Countries
6%
Heart Failure Outcomes
6%
Phase 3 Trial
6%
Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs)
6%
Escalating Dose
6%
Established Cardiovascular Disease
6%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Semaglutide
100%
Cardiovascular Disease
33%
Placebo
29%
Heart Failure with Preserved Ejection Fraction
20%
Heart Failure with Reduced Ejection Fraction
20%
Coronary Artery Atherosclerosis
8%
Obesity
8%
Adverse Event
4%
Heart Infarction
4%
Cerebrovascular Accident
4%
Glucagon Like Peptide 1 Receptor Agonist
4%
Diuretics
4%